Skip to content
Medical Health Aged Care

Get active and beat dementia in Perth!

Dementia Australia 2 mins read

The 2025 Perth Memory Walk & Jog is nearly here with the event taking place on 30 March at Burswood Park. 

 

Dementia Australia’s largest annual fundraising event returns to Perth in the hopes of attracting our biggest crowd yet, with participants helping to raise funds in support of people living with dementia, their families and carers.

 

Join MC Dementia Australia Ambassador Mark Gibson for a wonderful fun, family friendly day out. Each event is a fantastic opportunity for people impacted by dementia and their supporters to come together to walk or run, raise much-needed funds and to connect.  

 

An estimated 345 people live with dementia in the City of Perth council area. Dementia is the second leading cause of death of Australians and the leading cause of death of Australian women.

 

As the number of Australians impacted by dementia continues to grow, it is more important than ever that we raise funds and encourage everyone to get active for their brain health.

 

Get active and beat dementia, sign-up to participate in Memory Walk & Jog or volunteer at https://www.memorywalk.com.au/event/perth/home

 

Can’t attend Memory Walk & Jog but want to be involved? Organise your own group or individual walk or jog, with a MyWay event. Choose your own date and location and register at www.memorywalk.com.au/get-involved/mw. 

 

-Ends-

 

Dementia Australia is the source of trusted information, education and services for the estimated more than 433,300 Australians living with dementia, and the more than 1.7 million people involved in their care. We advocate for positive change and support vital research. We are here to support people impacted by dementia, and to enable them to live as well as possible. No matter how you are impacted by dementia or who you are, we are here for you.

For support, please contact the National Dementia Helpline on 1800 100 500. An interpreter service is available. The National Dementia Helpline is funded by the Australian Government. People looking for information can also visit dementia.org.au

Media contacts: Andrea Hogan, Media and Communications Manager, 0406 904 118, [email protected]

When talking or writing about dementia please refer to Dementia-Friendly Language Guidelines.

Note to Editors:

Photos and video of previous Memory Walk & Jog events for publication are available for use.

 

We request, where possible, details for the National Dementia Helpline 1800 100 500 appear alongside news stories about dementia, as these stories often prompt questions or concerns:

If this story has prompted any questions or concerns, please call the National Dementia Helpline 1800 100 500 (24 hours, 7 days a week) or visit dementia.org.au.

Media

More from this category

  • Medical Health Aged Care
  • 08/12/2025
  • 10:11
BeOne Medicines Ltd.

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies

Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLL Sonrotoclax in combination with BRUKINSA demonstrated rapid…

  • Contains:
  • Medical Health Aged Care
  • 08/12/2025
  • 09:40
Miltenyi Biomedicine

Miltenyi Biomedicine presents primary analysis of the pivotal DALY 2-EU trial for second-line relapsed/refractory large B-cell lymphoma at the 67th American Society of Hematology (ASH) Annual Meeting

DALY 2-EU results show zamtocabtagene autoleucel (zamto-cel) demonstrated clinically meaningful superiority over chemoimmunotherapy in patients with relapsed/refractory large B-cell lymphoma (r/r LBCL)1Zamto-cel was well-tolerated in the majority of patients. DALY 2-EU included a high-risk study population, characterized by older age and clinically high-risk disease featuresA 12-day manufacturing time resulted in a vein-to-vein time of 14-16 days, reducing the likelihood for bridging therapy.BERGISCH GLADBACH, Germany, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Miltenyi Biomedicine today announced results from the pivotal DALY 2-EU trial evaluating the efficacy and safety of zamtocabtagene autoleucel (zamto-cel) compared with standard chemoimmunotherapy (R-GemOx or Pola-BR) in patients with…

  • Medical Health Aged Care, Seniors Interest
  • 08/12/2025
  • 08:56
Monash University

Men and women may need different medications to avoid broken bones

A new international study, published in Osteoporosis International and led by Monash’s Centre for Medicine Use and Safety (CMUS), investigated the risks of a…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.